Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Cited by (1,002)

Items 501–600 of 1,002

1. Gastrointestinal complications of oncologic therapy
   Marta L. Davila, Robert S. Bresalier · 2008 · Nature Clinical Practice Gastroenterology &#38 Hepatology
2. Hemostatic Dysfunction in Paraproteinemias and Amyloidosis
   Maurizio Zangari, Francesca Elice, Louis M. Fink, Guido J. K. Tricot · 2007 · Seminars in Thrombosis and Hemostasis
3. Novel therapies for multiple myeloma
   Toshiaki Hayashi, Teru Hideshima, Kenneth Carl Anderson · 2002 · British Journal of Haematology
4. Treatment of relapsed and refractory multiple myeloma in the era of novel agents
   Niels W.C.J. van de Donk, Henk M. Lokhorst, Meletios Athanasios Dimopoulos, Michèle Cavo, Gareth John Morgan, Hermann Einsele, Martin H. Kropff, Steve Schey, Hervé Avet‐Loiseau, Heinz Ludwig et al. · 2010 · Cancer Treatment Reviews
5. A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145
   Michael J. Kovacs, Donna Ellen Reece, Deborah C. Marcellus, Ralph M. Meyer, Sarah Mathews, Rui-Ping Dong, Elizabeth A. Eisenhauer · 2006 · Investigational New Drugs
6. Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice
   Alexandre Chagas Santana, Sabrina Degaspari, Sérgio Catanozi, Humberto Dellê, Larissa de Sá Lima, Cleonice Silva, Paula L. Blanco, Kim Solez, Cristóforo Scavone, Irene L. Noronha · 2013 · Nephrology Dialysis Transplantation
7. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma
   Danai Daliani, Christos N. Papandreou, Peter F. Thall, Xuemei Wang, Cherie A. Perez, Rose Oliva, Lance C. Pagliaro, Robert John Amato · 2002 · Cancer
8. Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma
   S. Vincent Rajkumar, Paul Gerard Guy Richardson, Martha Q. Lacy, Angela A. Dispenzieri, Philip R. Greipp, Thomas Elmer Witzig, Robert L Schlossman, Carolyn Fowler Sidor, Kenneth Carl Anderson, Morie Abraham Gertz · 2007 · Clinical Cancer Research
9. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
   Sherif Shafik Farag, Shuhong Zhang, Buffy S. Jansak, Xiaojing Wang, Eric H. Kraut, Kenneth K. Chan, Janet Ellen Dancey, Michael R. Grever · 2009 · Leukemia Research
10. Decision-analytic refinements of the precautionary principle
    John D. Graham · 2001 · Journal of Risk Research
11. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials
    Antonio Pierangelo Palumbo, Anders Waage, Cyrille Hulin, Meral Beksaç, Sonja Zweegman, Francesca Gay, Peter Gimsing, Xavier P Leleu, Pierre Wijermans, Gülsan Türköz Sucak et al. · 2012 · Haematologica
12. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
    Christine I. Chen, Donna Ellen Reece, David Samuel DiCapua Siegel, Rubén Niesvizky, Ralph Vincent Boccia, Edward Allen Stadtmauer, Rafat Abonour, Paul Gerard Guy Richardson, Jeffrey Matous, Shaji Kunnathu Kumar et al. · 2009 · British Journal of Haematology
13. Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive and Rapidly Progressive Thyroid Carcinomas
    Kenneth B. Ain, Charles Lee, Kevin D. Williams · 2007 · Thyroid
14. Syndecan-1 in B lymphoid malignancies
    Ralph D. Sanderson, Magne Børset · 2002 · Annals of Hematology
15. From the bench to the bedside: emerging new treatments in multiple myeloma
    Constantine S. Mitsiades, Patrick John Hayden, Kenneth Carl Anderson, Paul Gerard Guy Richardson · 2007 · Best Practice & Research Clinical Haematology
16. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients
    Julia C. Sansbury, Barbara Cocuroccia, Joseph Lucius Jorizzo, Emanuela Gubinelli, Paolo Gisondi, Giampiero Girolomoni · 2004 · Journal of the American Academy of Dermatology
17. Emerging therapies for the treatment of relapsed or refractory multiple myeloma
    Meletios Athanasios Dimopoulos, Jesús F. San Miguel, Kenneth Carl Anderson · 2010 · European Journal Of Haematology
18. Design, synthesis and antitumor evaluation of novel thalidomide dithiocarbamate and dithioate analogs against Ehrlich ascites carcinoma-induced solid tumor in Swiss albino mice
    Magdy A. H. Zahran, Tarek Salem, Rehab Monir Samaka, Hussein S. Agwa, Ayman R. Awad · 2008 · Bioorganic & Medicinal Chemistry
19. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield
    Iris Breitkreutz, Henk M. Lokhorst, Marc‐Steffen Raab, Bronno van der Holt, Friedrich W. Cremer, D Herrmann, Axel G. Glasmacher, Ingo G.H. Schmidt‐Wolf, Igor Wolfgang Blau, Hans Martin et al. · 2007 · Leukemia
20. Treatment of Myeloma: Cure vs Control
    S. Vincent Rajkumar · 2008 · Mayo Clinic Proceedings
21. Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging
    Thomas M. Moehler, Hans Hawighorst, Kai Neben, Gerlinde Egerer, Jens Hillengass, Regina Max, Axel Benner, Anthony Dick Ho, Gerhard van Kaick, Hartmut Goldschmidt · 2001 · International Journal of Cancer
22. Multiple myeloma: an odyssey of discovery
    Robert A. Kyle · 2000 · British Journal of Haematology
23. Measuring tumour vascular response to antivascular and antiangiogenic drugs
    Gillian M. Tozer · 2003 · British Journal of Radiology
24. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma
    Lisa K. Hicks, Adam E. Haynes, Donna Ellen Reece, Irwin Walker, Jordan A. Herst, Ralph M. Meyer, Kevin Imrie · 2008 · Cancer Treatment Reviews
25. Immunomodulating drugs for chronic lymphocytic leukaemia
    Asher Alban Chanan-Khan, Carl W. Porter · 2006 · The Lancet Oncology
26. The Emerging Role of Novel Therapies for the Treatment of Relapsed Myeloma
    Paul Gerard Guy Richardson, Teru Hideshima, Constantine S. Mitsiades, Kenneth Carl Anderson · 2007 · Journal of the National Comprehensive Cancer Network
27. Thalidomide as an anti‐cancer agent
    Shaji Kunnathu Kumar, Thomas Elmer Witzig, S. Vincent Rajkumar · 2002 · Journal of Cellular and Molecular Medicine
28. Drug repurposing for viral cancers: A paradigm of machine learning, deep learning, and virtual screening‐based approaches
    Faheem Ahmed, In Suk Kang, Kyung Hwan Kim, Arun Asif, Chethikkattuveli Salih Abdul Rahim, Anupama Samantasinghar, Fida Hussain Memon, Kyung Hyun Choi · 2023 · Journal of Medical Virology
29. Therapy‐related peripheral neuropathy in multiple myeloma patients
    Marta Morawska, Norbert Grząśko, Magdalena Kostyra, Jolanta Wojciechowicz, Marek Hus · 2014 · Hematological Oncology
30. The Tao of myeloma
    Lawrence Boise, Jonathan L. Kaufman, Nizar Jacques Bahlis, Sagar Lonial, Kelvin P. Lee · 2014 · Blood
31. Redox stress and signaling during vertebrate embryonic development: Regulation and responses
    Alicia R. Timme‐Laragy, Mark E. Hahn, Jason M. Hansen, Archit Rastogi, Monika A. Roy · 2017 · Seminars in Cell and Developmental Biology
32. Correlation of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes
    Doménico Ribatti, Giuseppe Polimeno, Angelo Vacca, Andrea Marzullo, Enrico Crivellato B, Beatrice Nico, Giuseppe Tiziano Lucarelli, Franco Dammacco · 2002 · Leukemia
33. Moving disease biology from the lab to the clinic
    Kenneth Carl Anderson · 2003 · Cancer
34. Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma
    Paul Gerard Guy Richardson, Kenneth Carl Anderson · 2004 · Journal of Clinical Oncology
35. Angiogenesis and vascular malformations: Antiangiogenic drugs for treatment of gastrointestinal bleeding
    Juergen Bauditz · 2007 · World Journal of Gastroenterology
36. Management of treatment-related adverse events in patients with multiple myeloma
    María‐Victoria Mateos · 2010 · Cancer Treatment Reviews
37. Solitary plasmacytoma of bone and asymptomatic multiple myeloma
    Meletios Athanasios Dimopoulos, Lia Angela Moulopoulos, Alice G. Maniatis, Raymond Alexanian · 2000 · Blood
38. Human T-cell lymphotropic virus type 1–transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells
    Marwan Eid El-Sabban, Raghida Abou Merhi, Hounaida Abi Haidar, Bertrand Arnulf, Hilda El-Khoury, Jihane Basbous, Julie Nijmeh, Hugues de Thé, Olivier Hermine, Ali A. Bazarbachi · 2002 · Blood
39. Thalidomide Therapy and Deep Venous Thrombosis in Multiple Myeloma
    S. Vincent Rajkumar · 2005 · Mayo Clinic Proceedings
40. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone
    Alessandro Corso, Angela Lorenzi, V. Terulla, F. Air�, Marzia Varettoni, Silvia Mangiacavalli, Patrizia Zappasodi, C. Rusconi, Mario Lazzarino · 2004 · Annals of Hematology
41. Theoretical Basis for the Activity of Thalidomide
    Christian Meierhofer, Stefan Dunzendorfer, Christian Josef Wiedermann · 2001 · BioDrugs
42. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
    Kai Neben, Thomas M. Moehler, Gerlinde Egerer, Alwin Kraemer, Jens Hillengaß, Axel Benner, Anthony Dick Ho, Hartmut Goldschmidt · 2001 · PubMed
43. Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma
    Xiu-Bao Chang, Yuanxiao Zhu, Chang‐Xin Shi, A. Keith Stewart · 2013 · Acta Biochimica et Biophysica Sinica
44. Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response
    Asher Alban Chanan-Khan, Kasyapa S. Chitta, Noreen Ersing, Aneel Paulus, Aisha Masood, Taimur Sher, Abhisek Swaika, Paul K. Wallace, Terry L. Mashtare, Greg E. Wilding et al. · 2011 · British Journal of Haematology
45. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNFα levels during treatment
    Apostolia Maria Tsimberidou, Tracey A. Waddelow, Hagop M. Kantarjian, Maher X. Albitar, Francis Joseph Giles · 2003 · Leukemia Research
46. Thrombosis in multiple myeloma
    Maurizio Zangari, Francesca Elice, Louis M. Fink, Guido J. K. Tricot · 2007 · Expert Review of Anticancer Therapy
47. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
    Pedram Razavi, Kristin A. Rand, Wendy Cozen, Asher Alban Chanan-Khan, Saad Z. Usmani, Sikander Ailawadhi · 2013 · Blood Cancer Journal
48. Molecular aspects of multiple myeloma
    Nikolaos G. Kastrinakis, Vassilis G. Gorgoulis, Periklis G. Foukas, Meletios Athanasios Dimopoulos, Ch. Kittas · 2000 · Annals of Oncology
49. Thalidomide is distributed into human semen after oral dosing.
    Steve K. Teo, Jill L. Harden, Alison B. Burke, Faruq H. Noormohamed, Mike S Youle, Margaret A. Johnson, Barry S. Peters, David Stirling, Steve D. Thomas · 2001 · PubMed
50. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion
    Kai Neben, Thomas M. Moehler, Alwin Kraemer, Axel Benner, Gerlinde Egerer, Anthony Dick Ho, Hartmut Goldschmidt · 2001 · British Journal of Haematology
51. Induced protein degradation for therapeutics: past, present, and future
    Hojong Yoon, Justine C. Rutter, Yen-Der Li, Benjamin L. Ebert · 2024 · Journal of Clinical Investigation
52. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
    Hugues de Lavallade, Jean El Cheikh, Catherine Faucher, Sabine Fürst, Stoppa Am, Diane Coso, Réda Bouabdallah, Christian Chabannon, J. A. Gastaut, Didier Blaise et al. · 2008 · Bone Marrow Transplantation
53. Plasmacytoma relapses in the absence of systemic progression post‐high‐dose therapy for multiple myeloma
    Evangelos Terpos, Katayoun Rezvani, Supratik Basu, Alison Milne, Peter E. Rose, Geoffrey L. Scott, Amin Rahemtulla, Diana Samson, Jane F. Apperley · 2005 · European Journal Of Haematology
54. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma
    Ramón García‐Sánz, Maria Isabel González-Fraile, Magdalena Sierra, Carlos López, Marcos González, Jesús F. San Miguel · 2002 · The Hematology Journal
55. Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity
    Wei Wang, Masaaki Adachi, Rina Kawamura, Hiroki Sakamoto, Toshiaki Hayashi, Tadao Ishida, Kohzoh Imai, Yasuhisa Shinomura · 2006 · APOPTOSIS
56. Thromboembolic events during treatment with thalidomide
    Eleonora Urbauer, Hannes Kaufmann, Thomas Nösslinger, Markus Raderer, Johannes W. Drach · 2002 · Blood
57. Thalidomide and immunomodulatory drugs as cancer therapy
    Noopur S Raje, Kenneth Carl Anderson · 2002 · Current Opinion in Oncology
58. Current strategies for treatment of relapsed/refractory multiple myeloma
    Jacob P. Laubach, Peter Michael Voorhees, Hani Hassoun, Andrzej J. Jakubowiak, Sagar Lonial, Paul Gerard Guy Richardson · 2014 · Expert Review of Hematology
59. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
    Noopur S Raje, Teru Hideshima, Siddhartha Mukherjee, Marc Steffen Raab, Sonia Vallet, Shweta Chhetri, Diana D. Cirstea, Samantha Pozzi, Constantine S. Mitsiades, Melissa Rooney et al. · 2009 · Leukemia
60. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma
    Stéphane Supiot, Alain Faivre-Chauvet, Olivier Couturier, Marie‐Françoise Heymann, Nelly Robillard, Françoise Kraeber‐Bodéré, Laurence Morandeau, Michelle Mah, Michel Ch�rel · 2002 · Cancer
61. Multiple Myeloma
    S. Vincent Rajkumar · 2009 · Current Problems in Cancer
62. PC cell-derived growth factor (granulin precursor) expression and action in human multiple myeloma.
    Wengang Wang, Jun Hayashi, Wes E. Kim, Ginette Serrero · 2003 · PubMed
63. Arsenic Trioxide: An Emerging Therapy for Multiple Myeloma
    Nikhil C. Munshi · 2001 · The Oncologist
64. Antiangiogenesis in haematological malignancies
    William W. Li, Michelle Hutnik, Gerald Gehr · 2008 · British Journal of Haematology
65. Multiple myeloma – an update on diagnosis and treatment
    Jo Caers, Isabelle Vande Broek, Hendrik De Raeve, Lucienne Michaux, Fabienne Trullemans, Rik Schots, Ben Van Camp, Karin Vanderkerken · 2008 · European Journal Of Haematology
66. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group
    Konstantinos Zervas, Dimitra Mihou, Eirini Katodritou, Anastasia G. Pouli, C. Mitsouli, Αchilles Anagnostopoulos, Souzana Delibasi, Maria‐Christina Kyrtsonis, Nicolaos Anagnostopoulos, Evangelos Terpos et al. · 2007 · Annals of Oncology
67. In Vitro Screening for Drug Repositioning
    Graeme F. WILKINSON, Kevin Pritchard · 2014 · SLAS DISCOVERY
68. Thalidomide and its analogues in the treatment of Multiple Myeloma
    Tahir Latif, Nabeel Chauhan, Rashid Z Khan, Andrea E. Moran, Saad Z. Usmani · 2012 · Experimental Hematology and Oncology
69. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.
    Stig Lenhoff, Martin Hjorth, Ingemar Turesson, Jan Westin, Peter Gimsing, Finn Wislöff, Lucia Ahlberg, Kristina Elisabet Carlson, Ilse Christiansen, Inger Marie S. Dahl et al. · 2006 · PubMed
70. Re‐evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents
    Dimitrios Maltezas, Meletios Athanasios Dimopoulos, Irene Katodritou, Panagiotis Repousis, Anastasia G. Pouli, Evangelos Terpos, Panayiotis G. Panayiotidis, Sossana Delimpasi, Evridiki Michalis, Konstantinos Anargyrou et al. · 2012 · Hematological Oncology
71. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis
    Flora Zagouri, Efstathios Kastritis, Maria Gavriatopoulou, Theodoros Ν. Sergentanis, Θεοδώρα Ψαλτοπούλου, Evangelos Terpos, Meletios Athanasios Dimopoulos · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
72. Targeting Reactive Oxygen Species Capacity of Tumor Cells with Repurposed Drug as an Anticancer Therapy
    Jiabing Wang, Dongsheng Sun, Lili Huang, Shijian Wang, Yong Hyun Jin · 2021 · Oxidative Medicine and Cellular Longevity
73. Thalidomide Inhibits Tumor Necrosis Factor-α Production and Antigen Presentation by Langerhans Cells
    Liang Deng, Wanhong Ding, Richard D. Granstein · 2003 · Journal of Investigative Dermatology
74. Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo
    Giovanna Cutrona, Manlio Ferrarini · 2001 · Blood
75. Durable Responses to Thalidomide-Based Drug Therapy for Myelofibrosis With Myeloid Metaplasia
    Ruben A. Mesa, Michelle Ann Elliott, Georgene S. Schroeder, Ayalew Tefferi · 2004 · Mayo Clinic Proceedings
76. Microarray‐based understanding of normal and malignant plasma cells
    John De Vos, Dirk Hose, Thierry X. Reme, Karin Tarte, Jérôme Moreaux, Karène Mahtouk, Michel Jourdan, Hartmut Goldschmidt, Jean‐François Rossi, Friedrich W. Cremer et al. · 2006 · Immunological Reviews
77. Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation
    Qinglin Shi, Lijuan Chen · 2017 · Journal of Immunology Research
78. Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant
    A. Keith Stewart, Christine I. Chen, Kang Howson‐Jan, Darrell J. White, Jean Roy, Michael J. Kovacs, Chaim Shustik, Anna Sadura, Lois E. Shepherd, Keyue Ding et al. · 2004 · Clinical Cancer Research
79. Angiogenesis in hematologic malignancies
    Thomas M. Moehler, Kai Neben, Anthony Dick Ho, Hartmut Goldschmidt · 2001 · Annals of Hematology
80. High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
    Antonio Giovanni Solimando, Matteo Da Vià, Sebastiano Cicco, Patrizia Leone, Giuseppe Di Lernia, Donato Giannico, Vanessa Desantis, Maria Antonia Frassanito, Arcangelo Morizio, Julia Delgado Tascon et al. · 2019 · Journal of Clinical Medicine
81. Radiotherapy and "new" drugs-new side effects?
    Maximilian Niyazi, Cornelius Maihöfer, Mechthild Krause, Claus Michael Rödel, Wilfried Budach, Claus Belka · 2011 · Radiation Oncology
82. New drugs for treatment of multiple myeloma
    Benedetto Bruno, Marcello Rotta, Luisa Giaccone, Massimo Massaia, Alessandra Bertola, Antonio Palumbo, Mario Boccadoro · 2004 · The Lancet Oncology
83. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology
    Takumi Ito, Yuki Yamaguchi, Hiroshi Handa · 2021 · Cell chemical biology
84. Antimyeloma efficacy of thalidomide in the SCID-hu model
    Shmuel Yaccoby, Cherie L. Johnson, Susan Mahaffey, Michele J. Wezeman, Bart Barlogie, Joshua Epstein · 2002 · Blood
85. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy
    Khaled M. Musallam, Fadi S. Dahdaleh, Ali I. Shamseddine, Ali T. Taher · 2008 · Thrombosis Research
86. Elotuzumab for the treatment of multiple myeloma
    Yucai Wang, Larysa Jessica Sanchez, David Samuel DiCapua Siegel, Michael L. Wang · 2016 · Journal of Hematology & Oncology
87. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT
    Ebenezer David, Shi‐Yong Sun, Edmund K. Waller, Jing Chen, Fadlo Raja Khuri, Sagar Lonial · 2005 · Blood
88. Diagnosis and Management of Multiple Myeloma
    Scott A. Ely · 2002 · British Journal of Haematology
89. Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients
    Francisco Chung, Jun Lu, Brian D. Palmer, Philip Kestell, Peter Browett, Bruce C. Baguley, Malcolm Drummond Tingle, Lai‐Ming Ching · 2004 · Clinical Cancer Research
90. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain
    Susan E. Krown, Donna Niedzwiecki, Wen‐Jen Hwu, Lydia C. Hodgson, Alan N. Houghton, Frank G. Haluska, for the Cancer and Leukemia Group B · 2006 · Cancer
91. Effects of Putative Hydroxylated Thalidomide Metabolites on Blood Vessel Density in the Chorioallantoic Membrane (CAM) Assay and on Tumor and Endothelial Cell Proliferation.
    Megan G. Marks, Jiandong Shi, Michael O. Fry, Zili Xiao, Michelle Trzyna, Vedavalli N. Pokala, Michael A. Ihnat, Pui‐Kai Li · 2002 · Biological and Pharmaceutical Bulletin
92. Flubendazole induces mitochondrial dysfunction and DRP1-mediated mitophagy by targeting EVA1A in breast cancer
    Yongqi Zhen, Zhaoxin Yuan, Jiahui Zhang, Yao Chen, Yuning Fu, Yi Liu, Leilei Fu, Lan Zhang, Xian‐Li Zhou · 2022 · Cell Death and Disease
93. Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity
    Alexander L. Ruchelman, Hon‐Wah Man, Weihong Zhang, Roger Chen, Lori Capone, Jian Kang, Anastasia Parton, Laura G. Corral, Peter H Schafer, Darius M. Babusis et al. · 2012 · Bioorganic & Medicinal Chemistry Letters
94. Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma
    Marek Hus, Norbert Grząśko, Marta Szostek, Andrzej Pluta, Grzegorz Helbig, Dariusz Woszczyk, Maria Cioch, Dariusz Jawniak, Wojciech Maciej Legiec, Marta Morawska et al. · 2011 · Annals of Hematology
95. New Insights in Anti-Angiogenesis in Multiple Myeloma
    Doménico Ribatti, Angelo Vacca · 2018 · International Journal of Molecular Sciences
96. Pharmacokinetic Considerations of Oral Chemotherapy in Elderly Patients with Cancer
    J. Andrew Skirvin, Stuart M. Lichtman · 2002 · Drugs & Aging
97. Lenalidomide in multiple myeloma
    Paul Gerard Guy Richardson, Constantine S. Mitsiades, Teru Hideshima, Kenneth Carl Anderson · 2006 · Expert Review of Anticancer Therapy
98. Pharmacogenetic Associations ofCYP2C19Genotype with In Vivo Metabolisms and Pharmacological Effects of Thalidomide
    Yuichi Ando, Douglas K. Price, William L. Dahut, Michael Craig Cox, Eddie Reed, William Douglas Figg · 2002 · Cancer Biology & Therapy
99. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment
    Stephen Schey, Jamie D. Cavenagh, Roderick J. Johnson, J. Anthony Child, Heather E. Oakervee, Richard Wyn Jones · 2003 · Leukemia Research
100. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
     Madan, Sumit, Lacy, Martha Q., Dispenzieri, Angela, Gertz, Morie A., Buadi, Francis, Hayman, Suzanne R., Detweiler-Short, Kristen, Dingli, David, Zeldenrust, Steven, Lust, John et al. · 2011 · Blood